-
Sector Analysis
![]()
PharmaPoint: Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025
The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The...
-
Product Insights
![]()
Venous Thromboembolism Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Venous Thromboembolism Global Clinical Trials Review, H2, 2016" provides an overview of Venous Thromboembolism clinical trials scenario. This report provides top line data relating to the clinical trials on Venous Thromboembolism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
![]()
Consumer and Market Insights: Haircare in Mexico
Improving economy and a large young working population base will drive the Mexican Haircare market. The market is led by the Shampoo category, which is forecast to register fastest value growth during 2015-2020.Hypermarkets & Supermarkets is the leading distribution channel for Haircare products in the country. Rigid Plastics is the commonly used packaging material. L'Oreal S.A. and Procter & Gamble Company are the leading players in the market.
-
Sector Analysis
![]()
Major Depressive Disorder – US Drug Forecast and Market Assessment to 2025
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which...
-
Sector Analysis
![]()
Schizophrenia – US Drug Forecast and Market Analysis to 2025
Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions). A multitude of antipsychotic products are currently available for the pharmacological management of schizophrenia, many of which are already available as inexpensive generics. Further patent and exclusivity losses...
-
Sector Analysis
![]()
Schizophrenia – 5EU Drug Forecast and Market Analysis to 2025
Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions). A multitude of antipsychotic products are currently available for the pharmacological management of schizophrenia, many of which are already available as inexpensive generics. Further patent and exclusivity losses...
-
Sector Analysis
![]()
PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025
Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as...
-
Sector Analysis
![]()
OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025
Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission,...
-
Sector Analysis
![]()
Bipolar Disorder – Current and Future Players
GlobalData has released its pharma report, “Bipolar Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Bipolar Disorder Market. The report identifies and analyses the key companies shaping and driving the global Bipolar Disorder market. The report provides insight into the competitive Bipolar Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary...
-
Sector Analysis
![]()
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024
Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination that have a significant social impact through disruptions at school, work, home, and in relationships. The majority of children with the disorder will continue to experience symptoms into adolescence. 30-50% of children diagnosed with ADHD continue to have problems into adulthood resulting in 2-5% of adults having ADHD. Growth is expected in the global ADHD marketplace, despite the market being...
-
Sector Analysis
![]()
PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which...
-
Sector Analysis
![]()
PharmaPoint: Acute Coronary Syndrome – Global Drug Forecast and Market Analysis to 2025
Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue .In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable...
-
Sector Analysis
![]()
PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2025
Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual's deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins...
-
Sector Analysis
![]()
PharmaPoint: Atrial Fibrillation – Global Drug Forecast and Market Analysis to 2025
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially an antiarrhythmic drug for rhythm control. All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important...
-
Sector Analysis
![]()
OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence the outcomes and treatment decisions. Patients diagnosed with indolent NHLs (follicular lymphoma [FL] or marginal zone lymphoma [MZL]) can achieve a median survival of 10 to 20 years, and relative...
-
Sector Analysis
![]()
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an...
-
Product Insights
![]()
Regurgitation Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Regurgitation Global Clinical Trials Review, H1, 2016" provides an overview of Regurgitation clinical trials scenario. This report provides top line data relating to the clinical trials on Regurgitation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
![]()
Cryptococcosis Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Cryptococcosis Global Clinical Trials Review, H1, 2016" provides an overview of Cryptococcosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptococcosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
![]()
Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
![]()
Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Non-Hodgkin Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Hodgkin Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.